Target Price | €26.89 |
Price | €24.08 |
Potential | 11.66% |
Number of Estimates | 18 |
18 Analysts have issued a price target Bayer 2026 . The average Bayer target price is €26.89. This is 11.66% higher than the current stock price. The highest price target is €37.00 53.65% , the lowest is €22.00 8.64% . | |
A rating was issued by 20 analysts: 5 Analysts recommend Bayer to buy, 15 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Bayer stock has an average upside potential 2026 of 11.66% . Most analysts recommend the Bayer stock at Hold. |
16 Analysts have issued a sales forecast Bayer 2025 . The average Bayer sales estimate is €46.4b . This is 0.39% lower than the revenue of the last 12 months(TTM). The highest sales forecast is €47.1b 1.00% , the lowest is €45.6b 2.07% .
This results in the following potential growth metrics:
2024 | €46.6b | 2.16% |
---|---|---|
2025 | €46.4b | 0.39% |
2026 | €47.2b | 1.63% |
2027 | €48.3b | 2.28% |
2028 | €49.2b | 1.89% |
2029 | €50.3b | 2.37% |
16 Analysts have issued an Bayer EBITDA forecast 2025. The average Bayer EBITDA estimate is €9.4b . This is 10.13% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €10.1b 17.50% , the lowest is €9.0b 4.75% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €8.5b | 30.89% |
---|---|---|
2025 | €9.4b | 10.61% |
2026 | €9.9b | 4.62% |
2027 | €10.3b | 4.14% |
2028 | €10.3b | 0.48% |
2029 | €10.2b | 1.22% |
2024 | 18.30% | 29.37% |
---|---|---|
2025 | 20.32% | 11.04% |
2026 | 20.92% | 2.95% |
2027 | 21.30% | 1.82% |
2028 | 21.01% | 1.36% |
2029 | 20.27% | 3.52% |
10 Bayer Analysts have issued a net profit forecast 2025. The average Bayer net profit estimate is €2.1b . This is 182.66% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.6b 242.31% , the lowest is €1.3b 151.15% .
This results in the following potential growth metrics and future Net Margins:
2024 | €-2.6b | 13.04% |
---|---|---|
2025 | €2.1b | 182.66% |
2026 | €2.8b | 31.50% |
2027 | €3.2b | 14.32% |
2028 | €3.9b | 21.59% |
2029 | €4.2b | 8.47% |
2024 | -5.48% | 11.12% |
---|---|---|
2025 | 4.55% | 183.02% |
2026 | 5.88% | 29.23% |
2027 | 6.58% | 11.90% |
2028 | 7.85% | 19.30% |
2029 | 8.32% | 5.99% |
10 Analysts have issued a Bayer forecast for earnings per share. The average Bayer EPS is €2.15 . This is 182.69% higher than earnings per share in the financial year 2024. The highest EPS forecast is €3.70 242.31% , the lowest is €1.33 151.15% .
This results in the following potential growth metrics and future valuations:
2024 | €-2.60 | 13.04% |
---|---|---|
2025 | €2.15 | 182.69% |
2026 | €2.83 | 31.63% |
2027 | €3.23 | 14.13% |
2028 | €3.93 | 21.67% |
2029 | €4.26 | 8.40% |
Current | -9.27 | 5.82% |
---|---|---|
2025 | 11.20 | 220.82% |
2026 | 8.52 | 23.93% |
2027 | 7.45 | 12.56% |
2028 | 6.13 | 17.72% |
2029 | 5.65 | 7.83% |
Based on analysts' sales estimates for 2025, the Bayer stock is valued at an EV/Sales of 1.22 and an P/S ratio of 0.51 .
This results in the following potential growth metrics and future valuations:
Current | 1.21 | 3.97% |
---|---|---|
2025 | 1.22 | 0.48% |
2026 | 1.20 | 1.60% |
2027 | 1.17 | 2.23% |
2028 | 1.15 | 1.86% |
2029 | 1.12 | 2.31% |
Current | 0.51 | 6.17% |
---|---|---|
2025 | 0.51 | 0.39% |
2026 | 0.50 | 1.61% |
2027 | 0.49 | 2.23% |
2028 | 0.48 | 1.84% |
2029 | 0.47 | 2.33% |
Analyst | Rating | Action | Date |
---|---|---|---|
MWB RESEARCH AG |
Buy
➜
Buy
|
Unchanged | Jan 05 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Nov 28 2024 |
BERENBERG |
Hold
➜
Hold
|
Unchanged | Nov 25 2024 |
HSBC |
Hold
➜
Hold
|
Unchanged | Nov 24 2024 |
REDBURN ATLANTIC |
Neutral
➜
Neutral
|
Unchanged | Nov 19 2024 |
BNP PARIBAS EXANE |
Outperform
➜
Outperform
|
Unchanged | Nov 18 2024 |
STIFEL EUROPE |
Hold
➜
Hold
|
Unchanged | Nov 18 2024 |
Analyst Rating | Date |
---|---|
Unchanged
MWB RESEARCH AG:
Buy
➜
Buy
|
Jan 05 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Nov 28 2024 |
Unchanged
BERENBERG:
Hold
➜
Hold
|
Nov 25 2024 |
Unchanged
HSBC:
Hold
➜
Hold
|
Nov 24 2024 |
Unchanged
REDBURN ATLANTIC:
Neutral
➜
Neutral
|
Nov 19 2024 |
Unchanged
BNP PARIBAS EXANE:
Outperform
➜
Outperform
|
Nov 18 2024 |
Unchanged
STIFEL EUROPE:
Hold
➜
Hold
|
Nov 18 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.